Logo image of CHMA

Chiasma Inc (CHMA) Stock Fundamental Analysis

NASDAQ:CHMA - Nasdaq -

3.76  -0.24 (-6%)

After market: 3.78 +0.02 (+0.53%)

Fundamental Rating

2

Overall CHMA gets a fundamental rating of 2 out of 10. We evaluated CHMA against 198 industry peers in the Pharmaceuticals industry. CHMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CHMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CHMA has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -56.38%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -2408.65%
PM (TTM) -2968.35%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

CHMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -3.09, we must say that CHMA is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for CHMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.09
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 7.91 indicates that CHMA has no problem at all paying its short term obligations.
CHMA has a Quick Ratio of 7.08. This indicates that CHMA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 7.91
Quick Ratio 7.08

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CHMA have decreased strongly by -46.36% in the last year.
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.36% on average over the next years. This is quite good.
CHMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 280.08% yearly.
EPS Next Y12.13%
EPS Next 2Y22.91%
EPS Next 3Y28.31%
EPS Next 5Y15.36%
Revenue Next Year1731.35%
Revenue Next 2Y702.55%
Revenue Next 3Y405.04%
Revenue Next 5Y280.08%

3.3 Evolution

CHMA Yearly Revenue VS EstimatesCHMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
CHMA Yearly EPS VS EstimatesCHMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CHMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHMA Price Earnings VS Forward Price EarningsCHMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.42
CHMA Per share dataCHMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

CHMA's earnings are expected to grow with 28.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.91%
EPS Next 3Y28.31%

More info and screens

0

5. Dividend

5.1 Amount

CHMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Chiasma Inc

NASDAQ:CHMA (8/5/2021, 8:18:03 PM)

After market: 3.78 +0.02 (+0.53%)

3.76

-0.24 (-6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)03-03 2022-03-03/amc
Inst Owners0.88%
Inst Owner Change0%
Ins Owners2.83%
Ins Owner Change0%
Market Cap217.68M
Analysts80
Price Target9.28 (146.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 71.84
P/FCF N/A
P/OCF N/A
P/B 3.47
P/tB N/A
EV/EBITDA -1.42
EPS(TTM)-1.61
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.05
BVpS1.08
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.38%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -2408.65%
PM (TTM) -2968.35%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.91
Quick Ratio 7.08
Altman-Z -3.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
EPS Next Y12.13%
EPS Next 2Y22.91%
EPS Next 3Y28.31%
EPS Next 5Y15.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1731.35%
Revenue Next 2Y702.55%
Revenue Next 3Y405.04%
Revenue Next 5Y280.08%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A